IsoPlexis
Company that develops a single-cell detection system identifying patient immune responses
IsoPlexis is dedicated to accelerating the fight against cancer and a range of the world’s toughest diseases with our uniquely correlative, award-winning single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine & Fierce, are used globally to advance the field of single-cell biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.
Visit website: https://isoplexis.com/
IsoPlexis News
State of play of single-cell sequencing technology
Labiotech - 14-Oct-2019
Extreme personalised medicine realises there is no such thing as an average cell
Read more...